tiprankstipranks
Advertisement
Advertisement
ResMed price target lowered to $225 from $240 at Jefferies
PremiumThe FlyResMed price target lowered to $225 from $240 at Jefferies
13d ago
ResMed: MatrixCare Divestiture Sharpens SaaS Growth Outlook, Supports Attractive Valuation and Reiterated Buy Rating
Premium
Ratings
ResMed: MatrixCare Divestiture Sharpens SaaS Growth Outlook, Supports Attractive Valuation and Reiterated Buy Rating
15d ago
ResMed price target lowered to $276 from $321 at RBC Capital
Premium
The Fly
ResMed price target lowered to $276 from $321 at RBC Capital
15d ago
Resmed: Regulatory Risks and Margin Pressures Leave Limited Upside with Price Target Reiterated at $230 and Hold Rating Maintained
PremiumRatingsResmed: Regulatory Risks and Margin Pressures Leave Limited Upside with Price Target Reiterated at $230 and Hold Rating Maintained
16d ago
ResMed added to APAC Conviction List at Goldman Sachs
Premium
The Fly
ResMed added to APAC Conviction List at Goldman Sachs
22d ago
ResMed price target lowered to $266 from $290 at KeyBanc
Premium
The Fly
ResMed price target lowered to $266 from $290 at KeyBanc
1M ago
ResMed downgraded to Equal Weight from Overweight at Morgan Stanley
PremiumThe FlyResMed downgraded to Equal Weight from Overweight at Morgan Stanley
1M ago
ResMed price target lowered to $270 from $340 at Citi
Premium
The Fly
ResMed price target lowered to $270 from $340 at Citi
1M ago
Early notable gainers among liquid option names on June 3rd
Premium
The Fly
Early notable gainers among liquid option names on June 3rd
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100